Back

Impact of sodium-glucose cotransporter-2 inhibitors on recurrence after atrial fibrillation ablation in patients with indications for SGLT2i therapy

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and myocardial substrate Clinical Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ana Marta Castro Pinto

Hospital Guimaraes, Guimaraes (Portugal)

6 More presentations in this session

Presentation thumbnail
Beyond absolute epicardial fat: metabolic disproportionality predicts atrial fibrillation recurrence
Doctor F. Martins Nunes (Vila Nova de Gaia, PT)
Abstract
Presentation thumbnail
Atrial fibrillation in familial amyloid polyneuropathy: prevalence, clinical profile, and anticoagulation challenges
Doctor M. Pereira Santos (Porto, PT)
Abstract
Presentation thumbnail
Comparative effectiveness of existing medical therapy for atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM)
Ms S. Huang (Palo Alto, US)
Abstract
Presentation thumbnail
Prolonged postoperative atrial fibrillation (>48 Hours) identifies patients at risk of early and late heart failure and reduced survival after cardiac surgery
Assistant Professor M. Klinceva (Skopje, MK)
Abstract
Presentation thumbnail
Mechanical and electrical atrial remodelling: associations between left atrial strain, premature atrial contraction burden and p-wave indices in a population-based cohort
Mr H. Zilic (Malmo, SE)
Abstract

Access the full session

Session thumbnail
Atrial fibrillation and myocardial substrate

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Session
EHRA Myths - Device-detected atrial fibrillation
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources